– Codiak to provide data from ongoing exoSTING™ and exoIL-12™ clinical trials in late 1H 2022 –
– Anticipate first patients dosed in exoASO™-STAT6 Phase 1 clinical trial in 1H 2022 –
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
– Codiak to provide data from ongoing exoSTING™ and exoIL-12™ clinical trials in late 1H 2022 –
– Anticipate first patients dosed in exoASO™-STAT6 Phase 1 clinical trial in 1H 2022 –
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| CDAK | 0.0570 | -0.0725 | -55.98% |
| Codiak Biosciences Inc | |||